Who is sponsoring NCT00085774?

NCT00085774 is sponsored by Teva Branded Pharmaceutical Products R&D, Inc..

What drugs are being tested in NCT00085774?

Interventions in NCT00085774: albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI, placebo aerosol by HFA.

What condition does NCT00085774 study?

NCT00085774 studies Exercise-induced Bronchospasm.

Is NCT00085774 still recruiting?

NCT00085774 is currently completed. Last updated 24 November 2021.

Last reviewed 2021-11-24 · How we verify

NCT00085774

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Completed Phase 3 Last updated 24 November 2021

What this trial tests

Phase 3 trial testing albuterol aerosol by HFA MDI in Exercise-induced Bronchospasm in 24 participants. Completed in 30 September 2004.

Timeline

30 June 2004

Primary endpoint
30 September 2004

30 September 2004

Quick facts

Lead sponsor	Teva Branded Pharmaceutical Products R&D, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	24
Start date	30 June 2004
Primary completion	30 September 2004
Estimated completion	30 September 2004
Sites	3 locations across United States

Drugs / interventions tested

albuterol aerosol by HFA MDI — full drug profile →
albuterol aerosol by HFA BOI — full drug profile →
placebo aerosol by HFA — full drug profile →

Conditions studied

Exercise-induced Bronchospasm — all drugs for Exercise-induced Bronchospasm →

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc. — full company profile →

Who can join

Adults 12 to 40, any sex, with Exercise-induced Bronchospasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to examine the effectiveness of two bronchodilator inhalers in patients who have exercise-induced asthma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Teva Branded Pharmaceutical Products R&D, Inc. trials

Trials by the same sponsor.

NCT06664619 — A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate · Phase 3 · recruiting
NCT06627231 — Mass Balance Clinical Trial With TEV-56286 · Phase 1 · completed
NCT06480552 — An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Co · Phase 1 · recruiting
NCT06290102 — Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluti · Phase 1 · completed
NCT06253546 — Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00085774 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Teva Branded Pharmaceutical Products R&D, Inc.
Last refreshed: 24 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00085774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing